6 completed, 2 recruiting, 2 unknown, 1 withdrawn. 8 Phase 1, 5 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 4, Recruiting 2, Unknown 2 |
| Phase 2 | 5 | Unknown 2, Completed 1, Recruiting 1, Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
Follow Peptide Vaccine: new trials by email Literature Review of Peptide Vaccine trials Research Report on Peptide Vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine - Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5 | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 55 | 2026-06-28 | 2026-07-02 |
| Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC Peptide vaccine - NSCLC Stage IV, ALK Fusion Protein Expression | Phase 1 / Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 12 | 2024-05-13 | 2026-07-28 |
| A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma Bevacizumab, Peptide Vaccine, Poly-ICLC as immune adjuvant - Glioblastoma, Glioma | Phase 2 | Withdrawn | NYU Langone Health | 2016-11-01 | 2020-01-13 | |
| iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL Peptide Vaccine, Imiquimod - Leukemia, Chronic Lymphatic | Phase 2 | Completed | University Hospital Tuebingen | 56 | 2016-10-05 | 2022-11-28 |
| Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V) - Melanoma (Skin) | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 73 | 2010-08-13 | 2023-07-19 |
| Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 MART-1, NY-ESO-1, gp100:209-217(210M) - Melanoma (Skin) | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 127 | 2010-08-04 | 2023-01-18 |
| PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment Peptide Vaccine, Poly IC-LC - Prostate Cancer | Not applicable | Completed | H. Lee Moffitt Cancer Center and Research Institute | 29 | 2008-12-02 | 2019-10-04 |
| Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Peptide vaccine, GM-CSF, PF3512676 - Intraocular Melanoma, Malignant Conjunctival Neoplasm | Phase 1 | Completed | Ahmad Tarhini | 22 | 2008-10-01 | 2017-06-22 |
| Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer peptide vaccine - Gastric Cancer | Phase 1 | Completed | Kinki University | 9 | 2008-09-01 | 2012-04-06 |
| Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides peptide vaccine, Granulocyte Macrophage Colony Stimulating Factor, Montanide ISA-51 - Renal Cell Cancer, Advanced Renal Cell Cancer | Phase 1 / Phase 2 | Unknown | University Hospital Tuebingen | 40 | 2005-05-01 | 2017-08-17 |
| Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy Peptide vaccine, Montanide ISA-51, Granulocyte macrophage colony stimulating factor (GM-CSF) - Recurrent Prostate Cancer | Phase 1 / Phase 2 | Unknown | University Hospital Tuebingen | 36 | 2004-04-01 | 2017-08-17 |
Melanoma (3) · Prostatic Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Glioblastoma (1) · Glioma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Renal Insufficiency, Chronic (1) · Stomach Neoplasms (1) · Uveal Melanoma (1)
H. Lee Moffitt Cancer Center and Research Institute (3) · University Hospital Tuebingen (3) · Ahmad Tarhini (1) · Kinki University (1) · NYU Langone Health (1) · Ohio State University Comprehensive Cancer Center (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (7) · Germany (1) · Japan (1) · Puerto Rico (1)
Arnulf Stenzl, Prof. (2) · Ahmad A. Tarhini, MD, MS (1) · Hitoshi Shiozaki, MD (1) · Mayer Fishman, M.D., Ph.D. (1) · Nikhil I. Khushalani, M.D. (1) · Nikhil Khushalani, M.D. (1) · Sharon Gardner, MD (1) · Timothy J Voorhees, MD (1) · Vincent Lam, MD (1)
PMID 22495394, PMID 23613128, PMID 24145345, PMID 36450385, PMID 39660140, PMID 42720126